Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590317 · ClinicalTrials.gov registry record · Phase 2
Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department
A Phase 2 study of Nausea and Vomiting, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 2
- Study locations
NCT00590317: Completed Phase 2 study of Nausea and Vomiting, sponsored by Emory University.
NCT00590317 is a Phase 2 study of Nausea and Vomiting that has completed, run by Emory University. The registered enrollment target is 64 participants, below the 346-participant average among 6 other Nausea and Vomiting trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590317, a Phase 2 study of Nausea and Vomiting, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Prochlorperazine
Study Locations (2)
Georgia
- Grady Hospital - Atlanta
- Grady Memorial Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-03 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00590317 record still lists
NCT00590317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 346-participant average among 6 other Nausea and Vomiting trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Nausea and Vomiting appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron is the first listed.
NCT00590317 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00590317 about?
NCT00590317 is a clinical study titled "Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department". This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.
What is the current status of trial NCT00590317?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2005-03. Estimated completion is 2008-09.
What conditions does trial NCT00590317 study?
This clinical trial studies the following conditions: Nausea and Vomiting.
What interventions are being tested in trial NCT00590317?
The interventions under investigation include: Ondansetron (DRUG), Prochlorperazine (DRUG).
Who is sponsoring clinical trial NCT00590317?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00590317 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea and Vomiting
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
COMPLETED · Phase 2
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
COMPLETED · Phase 3
-
Patient Education in Preventing Nausea and Vomiting in Cancer Patients Receiving Chemotherapy
COMPLETED · NA
-
Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia